Dengue Vaccine Market Report 2024

This Dengue Vaccine market report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.

The dengue vaccine market size has grown rapidly in recent years. It will grow from $0.57 billion in 2023 to $0.64 billion in 2024 at a compound annual growth rate (CAGR) of 12%. The growth observed during the historic period can be attributed to several factors, including increased travel and urbanization, a rising demand for effective vaccines, a greater prevalence of exposure due to foreign travel, the expansion of healthcare services, and an increase in mass vaccination efforts.

The dengue vaccine market size is expected to see rapid growth in the next few years. It will grow to $1.02 billion in 2028 at a compound annual growth rate (CAGR) of 12.3%. The anticipated growth during the forecast period can be attributed to several factors, including the rising incidence of dengue, increased initiatives by various organizations, a growing number of clinical trials, and a heightened focus on multi-strain and tetravalent vaccine formulations. Key trends expected in this period include a rising demand for preventative vaccines, advancements in vaccine technology, the development of combination vaccines, an increase in research and clinical trials for new vaccine candidates, and a focus on enhancing vaccine efficacy and safety profiles.

The increasing number of dengue fever cases is anticipated to drive the growth of the dengue vaccine market in the coming years. Dengue fever is a viral infection transmitted by Aedes aegypti mosquitoes, leading to symptoms such as high fever, headaches, joint pain, and rashes. The rise in dengue cases can be attributed to factors such as climate change, urbanization, insufficient mosquito control, and the evolution of the virus. The dengue vaccine functions by activating the immune system to recognize and fight the dengue virus, reducing the severity of infections and lowering the risk of severe complications, which helps decrease the number of cases and hospitalizations. For example, in May 2024, the World Health Organization, based in Switzerland, reported that dengue cases in the Americas exceeded 7 million in April 2024, up from 4.6 million cases in 2023. Thus, the increasing incidence of dengue fever is propelling the growth of the dengue vaccine market.

Leading companies in the dengue vaccine market are focusing on developing advanced vaccine formulations, such as the dengue tetravalent vaccine, which enhances protection against all four dengue virus serotypes in a single vaccine. The dengue tetravalent vaccine provides immunity against the four dengue serotypes (DEN-1, DEN-2, DEN-3, and DEN-4), offering comprehensive protection against dengue fever. For instance, in December 2022, Takeda Pharmaceutical Company, a pharmaceutical firm based in Japan, received approval from the European Commission for the use of the QDENGA vaccine in individuals aged four years and older. This live-attenuated vaccine is used in several dengue-endemic countries to protect against the disease and utilizes weakened dengue serotype two viruses as a genetic basis for the other three serotypes. It is administered in two doses of 0.5 mL each, given at 0 and 3 months, targeting individuals from the age of four and older. A Phase 3 trial indicated that QDENGA has an efficacy of approximately 80.2% against dengue, with particularly favorable results in preventing hospitalizations. Its protection is expected to last around 4.5 years, which is longer than many other vaccines.

In February 2024, Takeda Pharmaceutical Company entered into a partnership with Biological E. Limited, a biotechnology and biopharmaceutical company based in India. This collaboration aims to expedite the production and accessibility of the QDENGA (TAK-003) dengue vaccine in endemic regions by increasing manufacturing capacity and providing multi-dose vials to support national immunization initiatives.

Major companies operating in the dengue vaccine market are Merck & Co. Inc., Sanofi Pasteur Limited, GlaxoSmithKline plc, Takeda Pharmaceutical Company, Sun Pharmaceutical Industries Ltd., Biological E. Limited, Saint Louis University, Indian Immunologicals Limited, Serum Institute of India Pvt. Ltd., Bavarian Nordic, Instituto Butantan, Bharat Biotech Ltd., Panacea Biotec Limited, SABIN Vaccine Institute, Medigen Vaccine Biologics Corporation, Emergex Vaccines Holding Ltd., BioNet-Asia Co. Ltd., Codagenix Inc., KM Biologics Co. Ltd., Chula Vaccine Research Center, Imutex Ltd.

Asia-Pacific was the largest region in the dengue vaccine market in 2023. North America is expected to be the fastest-growing region in the forecast period. The regions covered in the dengue vaccine market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the dengue vaccine market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

A dengue vaccine is a biological preparation aimed at preventing dengue fever, a viral disease transmitted by mosquitoes and caused by the dengue virus (DENV). When exposed to the virus in the future, dengue vaccines help stimulate the body's immune system to recognize and combat the dengue virus.

The primary types of dengue vaccines include live attenuated vaccines, chimeric live attenuated vaccines, inactivated vaccines, subunit vaccines, and nucleic acid-based vaccines. Live attenuated vaccines utilize a weakened form of the virus to elicit an immune response, training the body to fight dengue without causing the illness. These vaccines undergo various phases of development, including phase I, phase II, and phase III trials, and treatments associated with dengue may involve diuretics, anti-allergics, blood thinners, among others. They can be administered through different routes, such as oral and parenteral, and are used by a variety of end users, including hospitals, clinics, government institutions, and non-governmental organizations.

The dengue vaccines market research report is one of a series of new reports that provides dengue vaccines market statistics, including dengue vaccines industry global market size, regional shares, competitors with a dengue vaccines market share, detailed dengue vaccines market segments, market trends, and opportunities, and any further data you may need to thrive in the dengue vaccines industry. This dengue vaccines market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The dengue vaccine market consists of revenues earned by entities by providing treatment such as chlorothiazide, chlorthalidone, hydrochlorothiazide, and fexofenadine. The market value includes the value of related goods sold by the service provider or included within the service offering. The dengue vaccine market also includes sales of diagnostic kits, combination vaccines, clinical trial products, and post-vaccination monitoring tools. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.